On Friday, the Vetr crowd upgraded their rating of Regeneron Pharmaceuticals Inc REGN from 4 stars (buy), issued two days ago, to 4.5 stars (strong buy). Expectation for the stock is high with 83 percent of user ratings bullish.
After hitting a peak of $444.52 last week, Regeneron shares closed last week out a little lower at $397.48. This following a sizeable drop in healthcare stock at the start of Tuesday’s session, which saw a 5 percent fall and a 7 percent drop for Valeant Pharmaceuticals Intl Inc VRX.
See how crowdsourced ratings could help you time the market.
The Vetr crowd has Regeneron’s average target price at $461.47, which is below the average analyst price of $471.38. Less than 2 percent of Vetr users are holding REGN in their watch lists.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Your update on what’s going on in the Fintech space. Keep up-to-date with news, valuations, mergers, funding, and events. Sign up today!